• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 感染中的中和抗体滴度。

Neutralizing antibody titres in SARS-CoV-2 infections.

机构信息

School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.

Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.

出版信息

Nat Commun. 2021 Jan 4;12(1):63. doi: 10.1038/s41467-020-20247-4.

DOI:10.1038/s41467-020-20247-4
PMID:33397909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7782739/
Abstract

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT) and 50% (PRNT) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT antibody titres to decrease by half (T) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT and PRNT antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.

摘要

SARS-CoV-2 大流行是一个世纪以来全球面临的最大公共卫生挑战。中和抗体是保护的相关因素,需要有关病毒中和抗体反应动力学的数据。我们检测了来自 195 例经逆转录聚合酶链反应(RT-PCR)确诊的 SARS-CoV-2 感染的观察性队列的 293 份血清,这些血清是在症状出现后 0 至 209 天采集的。在 115 份≥61 天采集的血清中,使用蚀斑减少中和(PRNT)测定法进行了测试,其中 99.1%在 90%(PRNT)和 50%(PRNT)中和终点上仍保持血清阳性。我们估计,PRNT 滴度下降到严重、轻度和无症状患者的滴度为 1:10 的检测限,分别需要至少 372、416 和 133 天。在症状出现后 90 天(或无症状感染的初始 RT-PCR 检测),严重、轻度和无症状感染中 PRNT 抗体滴度减半(T)分别需要 69、87 和 31 天。患有严重疾病的患者比患有轻度或无症状感染的患者具有更高的峰值 PRNT 和 PRNT 抗体滴度。即使考虑到严重程度,年龄似乎也不会影响抗体反应。我们的结论是,SARS-CoV-2 感染会在大多数个体中引发强大的中和抗体滴度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/6af417de29bb/41467_2020_20247_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/44e465ce522e/41467_2020_20247_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/f39c8e67584d/41467_2020_20247_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/b7961824268e/41467_2020_20247_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/6af417de29bb/41467_2020_20247_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/44e465ce522e/41467_2020_20247_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/f39c8e67584d/41467_2020_20247_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/b7961824268e/41467_2020_20247_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8417/7782739/6af417de29bb/41467_2020_20247_Fig4_HTML.jpg

相似文献

1
Neutralizing antibody titres in SARS-CoV-2 infections.SARS-CoV-2 感染中的中和抗体滴度。
Nat Commun. 2021 Jan 4;12(1):63. doi: 10.1038/s41467-020-20247-4.
2
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.COVID-19 患者体内针对 SARS-CoV-2 的中和抗体反应。
Indian J Med Res. 2020;152(1 & 2):82-87. doi: 10.4103/ijmr.IJMR_2382_20.
3
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.对 COVID-19 康复者的抗体动态进行纵向分析显示,感染后长达 16 个月仍存在中和反应。
Nat Microbiol. 2022 Mar;7(3):423-433. doi: 10.1038/s41564-021-01051-2. Epub 2022 Feb 7.
4
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.疾病严重程度、发热、年龄和性别与 SARS-CoV-2 中和抗体反应相关。
Front Immunol. 2021 Jan 29;11:628971. doi: 10.3389/fimmu.2020.628971. eCollection 2020.
5
Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.无症状 COVID-19 感染者体内针对 SARS-CoV-2 的抗体动态变化。
Allergy. 2021 Feb;76(2):551-561. doi: 10.1111/all.14622. Epub 2020 Oct 26.
6
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.
7
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.康复的 COVID-19 患者体内抗 SARS-CoV-2 抗体的特征。
Viruses. 2021 Apr 16;13(4):697. doi: 10.3390/v13040697.
8
Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.评估针对 SARS-CoV-2 的体液免疫:蚀斑减少中和试验的验证和常规及替代中和测定法的多实验室比较。
Microbiol Spectr. 2021 Dec 22;9(3):e0088621. doi: 10.1128/Spectrum.00886-21. Epub 2021 Nov 17.
9
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.巴西恢复期血浆中 SARS-CoV-2 抗体筛查:一项自愿恢复期供者计划的初步经验教训。
Transfusion. 2020 Dec;60(12):2938-2951. doi: 10.1111/trf.16065. Epub 2020 Sep 16.
10
Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19.严重 COVID-19 患者呼吸道样本中 SARS-CoV-2 的长时间细胞培养复制。
Clin Microbiol Infect. 2021 Jun;27(6):886-891. doi: 10.1016/j.cmi.2021.02.014. Epub 2021 Feb 22.

引用本文的文献

1
Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach.新冠疫苗有效性和免疫原性面临的挑战:一项采用系统方法的叙述性综述
Vaccines (Basel). 2025 Jul 24;13(8):789. doi: 10.3390/vaccines13080789.
2
Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.六种用于检测感染原始毒株和一系列新冠病毒变异株患者抗体的新冠病毒血清学检测方法的比较
Access Microbiol. 2025 Jul 7;7(7). doi: 10.1099/acmi.0.000974.v3. eCollection 2025.
3
Household clusters of SARS-CoV-2 Omicron subvariants contemporaneously sequenced from dogs and their owners.

本文引用的文献

1
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.
2
Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020.2020 年 8 月,香港健康成年人再次感染 SARS-CoV-2 的血清学反应。
Emerg Infect Dis. 2020 Dec;26(12):3076-3078. doi: 10.3201/eid2612.203833. Epub 2020 Oct 22.
3
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
从狗及其主人身上同时测序的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎亚变体的家庭聚集情况。
mSphere. 2025 Jul 2:e0007425. doi: 10.1128/msphere.00074-25.
4
Magnetic bead-based electrochemical surrogate virus neutralization test for quantification of antibody neutralizing efficiency.基于磁珠的电化学替代病毒中和试验用于定量抗体中和效率。
Biosens Bioelectron. 2025 Nov 1;287:117640. doi: 10.1016/j.bios.2025.117640. Epub 2025 May 30.
5
Calculation of COVID-19 disease burden using Monte Carlo simulation with dynamic disability weights and analysis of transmission characteristics.使用动态残疾权重的蒙特卡罗模拟计算COVID-19疾病负担并分析传播特征。
BMC Public Health. 2025 Jun 2;25(1):2041. doi: 10.1186/s12889-025-23273-3.
6
Detection of SARS-CoV-2 Reinfections Using Nucleocapsid Antibody Boosting.利用核衣壳抗体增强检测新型冠状病毒2型再感染
Emerg Infect Dis. 2025 May;31(5):958-966. doi: 10.3201/eid3105.250021.
7
Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的免疫和炎症后果及其在肾脏疾病中的意义。
Front Immunol. 2025 Feb 12;15:1376654. doi: 10.3389/fimmu.2024.1376654. eCollection 2024.
8
Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.免疫桥接试验:保护脆弱和免疫功能低下患者抵御不断演变的病原体的重要工具。
Vaccines (Basel). 2024 Dec 29;13(1):19. doi: 10.3390/vaccines13010019.
9
Comparative Analysis of Virology and Pathogenesis of SARS-CoV-2 and HIV Infections: Implications for Public Health and Treatment Strategies.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与人类免疫缺陷病毒(HIV)感染的病毒学及发病机制比较分析:对公共卫生和治疗策略的启示
Infect Drug Resist. 2025 Jan 15;18:269-283. doi: 10.2147/IDR.S498430. eCollection 2025.
10
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients.香港神经肌肉疾病患者接种三剂 BNT162b2 和科兴疫苗的中期免疫原性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2424615. doi: 10.1080/21645515.2024.2424615. Epub 2024 Nov 13.
冠状病毒抗体介导免疫的系统评价:动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
4
Seasonal coronavirus protective immunity is short-lasting.季节性冠状病毒的保护免疫作用是短暂的。
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.
5
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.2019 年冠状病毒病(COVID-19)通过全基因组测序确认为与严重急性呼吸综合征冠状病毒 2 株系不同的病毒再次感染。
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951. doi: 10.1093/cid/ciaa1275.
6
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.中和抗体与高感染率渔业船舶暴发期间人类免受 SARS-CoV-2 感染相关。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.02107-20.
7
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.COVID-19 和 SARS 病例以及未感染对照者的 SARS-CoV-2 特异性 T 细胞免疫。
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
8
Potently neutralizing and protective human antibodies against SARS-CoV-2.强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
9
Kinetics of viral load and antibody response in relation to COVID-19 severity.病毒载量和抗体反应动力学与 COVID-19 严重程度的关系。
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
10
High neutralizing antibody titer in intensive care unit patients with COVID-19.COVID-19 重症监护病房患者的高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.